TUDCA Benefits
Liver Support
The liver plays a huge role in your overall health and plays a major part in some of the most important functions in the body.
Including detoxification of harmful chemicals and microbes from your food and environment, immunity, hormone processing, digestion and even blood sugar control.
Therefore having a healthy liver is vitally important to overall health. Unfortuntely our modern lifestyle and dietary choices take a big toll on the liver.
Fortunetly through diet, life style and supplements we can dramatically improve the function and health of our livers. And TUDCA is a supplement that can have a dramatic benefit on the liver by helping improve bile flow and bile duct integrity.* Both of which are crucial in a healthy and well functioning liver.
Digestion Support
Many people now suffering from gut related issues such as digestive discomfort, acid reflux, leaky gut and absorption issues. Fixing gut health and digestion is multifacited approach and there is no one product or lifestyle choice that will fix everything. However using products that support digestion and the microbiome play a huge role in fixing the gut.And TUDCA can be a great way to improve digestion, in particular the digestion of fats. Bile is critical in the break down of fats so if your bile flow is poor or you have had your gall bladder removed then you are going to have a hard time breaking down fats as well as other nutrients from your food.
TUDCA may assist with this by helping to improve bile flow and bile duct integrity and therefore improving your fat digestion and nutrient absorption, especially fat soluable vitamins A, D, E, K as well as omega fatty acids.TUDCA may also assist with improving microbiome health via improved bile which is critical for destroying harmful bacteria.*
Cellular Health
The integrity and health of your cells is vitally important to your overall all health. And one of the most important factors in cellular health is your mitochondria, which are essentially the powerhouses of your cells.
And since the liver is responsible for so many processes it requires a lot of energy and therefore a lot of mitochondria. And it has been shown that TUDCA actually helps to protect the mitochondria in your cells by reducing the release of a molecule called BAX entering the mitochondria and causing it’s early death. Therefore improving mitochondria levels and function within the liver which can lead to an improvement in your overall health.*
![LVLUP Health TUDCA Double Strength 1 TUDCA Australia supplement bottle of capsules](https://images.squarespace-cdn.com/content/v1/5cbebbb2fd679352480bf9e0/48e67ca5-9256-4219-a166-70f27a36f7ae/TUDCA+Australia+supplement+bottle+of+capsules.jpg)
TUDCA Supplement Australia
TUDCA Dosing Instructions
Studies suggest taking anywhere between 250mg – 1500mg. Each capsule is 500mg and there are 60 capsules in a bottle.
When to take:
You can take TUDCA whenever you like. However we suggest taking it a night for maximum benefit. It can also be taken before fatty meals to improve digestion
Side Effects of TUDCA?
There are no known side effects of taking TUDCA, occasionally some people may encounter ‘detox symptoms’ or ‘Herxhiemer reaction’ such as tiredness or cold and flu like symptoms. These are just part of your bodies healing and should surpass in a few days or week.
Taste and Smell
TUDCA has a very potent Acetone-like smell and horrible taste. This is because TUDCA is a bile acid and we do not use excipients or fillers in our products. The smell and taste being so strong is indicative of the purity and quality of the product and is nothing to be concerned about; this taste is why we encapsulate it, but the smell is unavoidable!
TUDCA Research Studies
Bodewes, F., Wouthuyzen-Bakker, M., Bijvelds, M., Havinga, R., de Jonge, H., & Verkade, H. (2012). Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (Cftr) in mice. American Journal Of Physiology-Gastrointestinal And Liver Physiology, 302(9), G1035-G1042. doi: 10.1152/ajpgi.00258.2011
Invernizzi, P., Setchell, K. D., Crosignani, A., Battezzati, P. M., Larghi, A.,O’Connell, N. C., & Podda, M. (1999). Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis .Hepatology (Baltimore, Md.),29(2), 320–327. https://doi.org/10.1002/hep.5102902203.
Larghi, A.,Crosignani, A., Battezzati, P. M., De Valle, G., Allocca, M.,Invernizzi, P., Zuin, M., & Podda, M. (1997). Ursodeoxycholic and tauro ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Alimentary pharmacology & therapeutics,11(2), 409–414. https://doi.org/10.1046/j.1365-2036.1997.124295000.x4.
Panella, C.,Ierardi, E., De Marco, M. F., Barone, M., Guglielmi, F. W., Polimeno, L., & Francavilla, A. (1995). Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease?. The Italian journal of gastroenterology,27(5), 256–258.5.
Laukens, D., Devisscher, L., Van den Bossche, L., Hindryckx, P., Vandenbroucke, R. E., Vandewynckel, Y. P., Cuvelier, C., Brinkman, B. M., Libert, C.,Vandenabeele, P., & De Vos, M. (2014). Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. Laboratory investigation; a journal of technical methods and pathology,94(12), 1419–1430. https://doi.org/10.1038/labinvest.2014.1176.
Yoon, Y. M., Kim, S., Han, Y. S., Yun, C. W., Lee, J. H., Noh, H., & Lee, S. H.(2019).TUDCA-treated chronic kidney disease-derived hMSCs improvetherapeutic efficacy in ischemic disease via PrPC. Redox biology,22, 101144. https://doi.org/10.1016/j.redox.2019.1011447.
Vettorazzi, J. F., Ribeiro, R. A., Borck, P. C., Branco, R. C., Soriano, S., Merino, B., Boschero, A. C., Nadal, A., Quesada, I., & Carneiro, E. M. (2016). The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism: clinical and experimental,65(3), 54–63. https://doi.org/10.1016/j.metabol.2015.10.0218.
Yoon, Y. M., Kim,S., Han, Y. S., Yun, C. W., Lee, J. H., Noh, H., & Lee, S. H.(2019). TUDCA-treated chronic kidney disease-derived hMSCs improvetherapeutic efficacy in ischemic disease via PrPC. Redox biology,22, 101144. https://doi.org/10.1016/j.redox.2019.1011449.
Castro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R.,Rodrigues, C. M., & Gama, M. J. (2012). Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson’s disease. Molecular neurobiology,46(2), 475–486. https://doi.org/10.1007/s12035-012-8295-410.
Piazza, F., Montagnani, M., Russo, C., Azzaroli, F., Aldini, R., Roda, E., & Roda, A. (2000). Competition in liver transport between chenodeoxycholicacid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates’ protection of liver damage induced by chenodeoxycholic acid. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,32(4), 318–328. https://doi.org/10.1016/s1590-8658(00)80025-0
Reviews
There are no reviews yet.